Pharmacokinetic Profile and Clinical Efficacy of Long-Acting Risperidone: Potential Benefits of Combining an Atypical Antipsychotic and a New Delivery System

Author： Ereshefsky Larry  

Publisher： Adis International

ISSN： 1174-5886

Source： Drugs in R&D, Vol.6, Iss.3, 2005-01, pp. : 129-137

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia

By Bhanji N.H.   Chouinard G.   Margolese H.C.  

European Neuropsychopharmacology, Vol. 14, Iss. 2, 2004-03 ,pp. : 87-92

Elsevier

Access to resources Recommend Favorite

Long-Acting Antipsychotic Medications

By  

Current Drug Targets, Vol. 13, Iss. 4, 2012-04 ,pp. : 555-560

Bentham Science Publishers

Access to resources Recommend Favorite

Long-Acting Injectable Risperidone for the Treatment of Schizophrenia: Clinical Perspectives

By Möller Hans-Jürgen  

Drugs, Vol. 67, Iss. 11, 2007-01 ,pp. : 1541-1566

Adis International

Access to resources Recommend Favorite

Pharmacokinetic and behavioral characterization of a long-term antipsychotic delivery system in rodents and rabbits

By Metzger Kayla   Shoemaker Jody   Kahn Jonathan   Maxwell Christina   Liang Yuling   Tokarczyk Jan   Kanes Stephen   Hans Meredith   Lowman Anthony   Dan Nily   Winey Karen   Swerdlow Neal   Siegel Steven  

Psychopharmacology, Vol. 190, Iss. 2, 2007-02 ,pp. : 201-211

Springer Publishing Company

Access to resources Recommend Favorite

Spotlight on Long-Acting Risperidone in Schizophrenia

By Tracy Swainston Harrison   Karen L. Goa  

American Journal of Drug Delivery, Vol. 2, Iss. 3, 2004-01 ,pp. : 207-210

Adis International

Access to resources Recommend Favorite